Novartis

Goal disorientation and lack of vision

Biotech

Evommune’s phase 2b flops, ending challenge to Novartis in hives

A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis for a skin disease market.

Nick Paul Taylor Jun 29, 2026 10:00am

Antares and Rho Ophiuchi cloud complex in the Sagittarius constellation

Novartis pays Antares $105M to tackle undruggable cancer targets

Jun 24, 2026 9:13am

NVS

Novartis dystrophy data tee up regulatory talks on Avidity drug

Jun 12, 2026 4:30am

glue scissors art supplies

Novartis sticks 2nd deal with Orionis, this one worth up to $1.4B

Jun 10, 2026 8:21am

Berlin Germany Brandenburg Gate

Fierce Pharma

Lilly, Boehringer slash investment plans in Germany

Jun 3, 2026 3:10pm

Brain scan neuroscience

Novartis ‘always looking’ for new ways to shuttle drugs to brain

May 28, 2026 8:44am